Roche currently has only one drug, Lucentis, in ophthalmology which it developed in collaboration with Novartis. In 2021, Roche's seventh top revenue generating drug was Herceptin (trastuzumab). Trefis Team for Quick Analysis with our professional Research Service: Toplists & Rankings: Best Employers Portal. Roche sets the gantenerumab expectations. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027. Looking forward, this trend could continue with Roches share declining to 41% in 2021, as it is expected to continue to grow at a slower pace, when compared to the overall market. . In Vitro Diagnostics : Diagnostic tests are medical tests performed to help in detection of diseases, conditions, or infections. Lucentis is an injectable medicine for the treatment of patients with Wet Age-Related Macular Degeneration (AMD). : Revenues reported in this division consist of Roche's central nervous system drugs. Herceptin is also a blockbuster drug for Roche with annual sales of close to $7.0 billion in 2016-2018. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares until 2021. We are looking to add expertise to the team and require previous experience in Cell and Gene Therapies, First in . Trefis->. It Competes With Pfizers Xalkori. Within pharmaceuticals, other alternatives are Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Merck, Abbvie, GlaxoSmithKline, and Teva, among others. The HER2-targeted breast cancer drug Perjeta (pertuzumab), which became Roche's top-selling oncology drug last year, contributed CHF 993 million in Q1 2022, a 2 percent increase from the year-ago quarter. Oct 17, 2022 (The Expresswire) -- "Oncology and Cancer Drugs Market" Insights 2022 By Types, Applications, Regions and Forecast to 2028. Roche is a pioneer in oncology research with a very high success rate in early diagnosis and targeted therapy. : Immunology area deals with diseases in which the immune system attacks the body's own cells. Roches oncology drugs sales accounted for 50% of the companys total revenues in 2016. Latitude: 42.6555575 Longitude: 23.37143 Images: < > Similar Places: 1. It is concerned with the diagnosis, therapy (surgery, chemotherapy, radiotherapy and other modalities) and care of patients with cancer, screening efforts of populations and follow-up care for successful cancer treatments. No value means no data was given. Roches Revenue Has Been On A Rise Over The Last Few Years, Comparing Roches Sales Growth To Its Peers. Graduate 1 and 2 data are "not yet in house", but a pooled analysis beckons in the event of one study failing. Accessed November 08, 2022. https://www.statista.com/statistics/266529/pharmaceutical-company-roche-top-drugs-based-on-revenue/, Roche. In Diagnostics, Roche competes with Abbott Labs, Siemens, GE Healthcare, Johnson & Johnson, Novartis, and Hitachi Medical Corp, among others. Segment by Type - Antimetabolite Create new scenarios to try different combinations of driver modifications, Reset one of your driver modifications in this scenario in order to modify another driver. Access to this and all other statistics on 80,000 topics from, Show sources information Roche Holding (RHHBY) operates in a pharmaceuticals segment and a diagnostics segment. The drug generated about 2.7 billion. The pharmaceutical segment's sales in 2015 amounted to 37.3 billion swiss francs, or about $37.8 billion,. Roche Avastin (bevacizumab) ranked sixth with sales of US$5.321 billion, a 25% decrease from 2019, mainly due to the impact of biosimilar drugs . Do Not Sell My Personal Information (CA Residents Only). The drug has seen strong growth with annual sales of around $7.0 billion in 2016-2018. NEW YORK - Roche reported before markets opened on Thursday a 4 percent increase in pharmaceutical revenues in the second quarter of 2021, showing signs of recovery from the negative impact of the COVID-19 pandemic.. Region: Global. It reports its in vitro diagnostics segment into four categories: Centralized And Point of Care Solutions, Tissue Diagnostics, Molecular Diagnostics, and Diabetes Care. Where are the coordinates of the Oncology Clinic Sofia? The company also has a leading market position in in-vitro diagnostics. You can only download this statistic as a Premium user. Other Smaller Drugs Include Takedas Alunbrig And Novartis Zykadia. Roche Holding's (NASDAQ:RHHBY) oncology portfolio is its largest therapeutic area and it will likely remain flat with revenues of around $29 billion over the next few years, as growth in sales. Roche Holding AG annual revenue for 2020 was $64.362B, a 0.31% increase from 2019. However, it also will lose the market exclusivity this year, and face generic competition from Pfizers Trazimera, which is a biosimilar for Herceptin, and it was approved by the U.S. FDA in March 2019. Roche's Oncology Drugs segment to make 43% of $64.0 billion in Roche's 2020 revenues, but Roche's Neuroscience Drugs segment is key to the company's revenue growth Oncology Drugs segment expected . Roche confirmed its revenue outlook for 2022, expecting sales to grow in the low-single digits at constant exchange rates. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Opinions expressed by Forbes Contributors are their own. The Roche Group reported CHF 15.78 billion ($17.19 billion) in total sales during the three months ended June 30, up 14 percent from CHF 14.14 billion in Q2 2020. NASDAQ and other For more than 50 years, Roche has been developing innovative diagnostics and therapies with the goal to transform cancer care. Trefis is an interactive financial community structured around trends, forecasts and insights related to some of the most popular stocks in the US. The near term growth will likely be led by the companys relatively newer drugs, including Perjeta, Kadcyla, Tecentriq, and Alecensa. The figure declined to 47% in 2018, amid slower growth from the oncology portfolio, when compared to some of the companys other divisions, such as immunology and neuroscience. Roche Latest Developments. Tecentriq Is Used For The Treatment of Advanced Urothelial Carcinoma, Metastatic Non-Small Cell Lung Cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer, In Combination Treatment of Metastatic Triple-Negative Breast Cancer. Directly accessible data for 170 industries from 50 countries The global market for oncology pharmaceuticals should grow from $177.4 billion in 2021 to $313.7 billion by 2026, at a compound annual growth rate (CAGR) of 12.1% for the period of 2021-2026. "Selected leading drugs of pharmaceutical company Roche in 2020 and 2021, based on revenue (in million Swiss francs)." It has seen a decline in sales to $5.3 billion in 2018, and it could decline to less than $4 billion in 2021. CellCept is a medication to fight the body's own immune system, which can reject a kidney, liver, or heart transplant. It is estimated to grow to around $8.0 billion by 2022, according to our estimates. Table 61. Roche, along with its American subsidiary Genentech, is the biggest player in the oncology market. NYSE/AMEX data delayed 20 minutes. As of 2020, Bristol-Myers Squibb (BMS) has once again secured the top position with total revenue of $29.73B, followed by Roche and Merck Oncology Segment Revenue: $0.037B Founded Year: 1984 Written by MabThera/Rituxan is another multi-billion dollar drug for Roche, with sales of $5.9 billion in 2016. There are about several kinds of viruses which cause diseases in human beings. 9. Create your Watchlist to save your favorite quotes on Nasdaq.com. All rights reserved. Neuroscience drugs revenues, which includes Ocrevus and Madopar among other drugs, will be the fastest-growing segment adding $3.7 billion over 2017-2020 (32% of $11.6 billion in incremental revenues). Credit Suisse Stock Missed The Street Expectations In Q3, What To Expect? In fact,we calculate$3 billion in expected lost sales from patent losses of these drugs. Roches share has declined from around 58% in 2016 to 45% in 2018, as other pharmaceutical companies, such as Merck, saw explosive growth in their oncology drugs sales. How Can Roches New Drugs Add $5 Billion In Oncology Sales By 2021? Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Roche will soon face biosimilar competition for its older oncology drugs ~ Avastin, Herceptin, and Rituxan. Hemlibras peak sales are estimated to be over $5 billion, thereby boosting the segment revenues over the next few years. Roche Main Business. Roches total revenue grew from $52.5 billion in 2015 to $64.4 billion in 2019. Roches diabetes care is focused on developing diagnostic instruments for detection of diabetes and also helps in glucose monitoring. Greater understanding of cancer biology combined with technological advancements allows us to deliver industry-leading diagnostics. Dear Shareholders, Since its founding 125 years ago, Roche has worked to improve the health and lives of countless people all over the world. Other Therapeutic Drugs : This represents Roche's drugs in other therapeutic areas (excluding the other segments), including metabolism, cardiovascular, and Haemophilia A among others. Roche has the largest oncology drug market share in the world with a range of successful products, such as Avastin, Herceptin, and Rituxan. Explore example interactive dashboards and create your own. Its drugs are used for the treatment of various types of diseases, including cancer, heart-related, and infectious, among others. 143 Pages. F5 Inc. Stock Set For Bounce After Dismal Post-Earnings Performance? At Roche we deliver a broad and growing selection of advanced research tools that accelerate life science discovery. Opinions expressed by Forbes Contributors are their own. See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams |Product, R&D, and Marketing Teams, This is a BETA experience. If you are an admin, please authenticate by logging in again. Oncology Global oncology market size in 2021 187bn USD Roche's oncology share of pharmaceuticals revenue in 2021 45.4% Roche's leading cancer drug in 2021 Ocrevus Research and. Your options are: This interactive model has a minimum and/or maximum limit on the value for the current driver you are viewing. We estimate it to grow to $30.1 billion in 2020 but decline thereafter to a little under $30.0 billion in 2022. Looking at the infectious diseases drugs portfolio, the sales declined from $2.3 billion in 2015 to $1.1 billion in 2019, and they will likely hover around the same mark over the next few years. Herceptin is a drug used in the treatment of some types of breast cancer. Roches sales grew at a CAGR of 5.3% between 2015 and 2019, higher than its peers. Oncology drugs are expected to be the single-biggest revenue driver with $30.1 billion in revenues (45% of Total Revenues), which is 5.7x the size of its Neuroscience drugs revenue in 2020. These States Could Legalize Marijuana Tomorrow. You need a Statista Account for unlimited access. Some common viral diseases are influenza, HIV/AIDS and Hepatitis. These diseases include rheumatoid arthritis, Crohns disease, addison's disease, multiple sclerosis, and type I diabetes. This driver cannot be modified within this scenario. Copy and paste multiple symbols separated by spaces. Profit from the additional features of your individual account. In, Roche. Then you can access your favorite statistics via the star in the header. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Professional diagnostic helps in identifying indications in various therapeutic areas such as oncology, cardiovascular, virology, and infectious diseases. The drug lost its marketing exclusivity last year, and it now faces biosimilar competition from Celltrion and Tevas Truxima. However, the sales could decline to $7.7 billion by 2022, as Xolair has lost its market exclusivity while Rituxan sales are also expected to decline amid biosimilar competition. 2, 2019. Roche Holdings (OTCMTS: RHHBY) revenue grew at a CAGR of 5.3% from $52.5 billion in 2015 to $64.4 billion in 2019, and it is estimated to top $66 billion in 2020, led by its Neuroscience drugs. To use individual functions (e.g., mark statistics as favourites, set of Foundation Medicine's revenue, with the assay developer recording $14.648 . It owns some of the best-selling brands including Avastin, Rituxan and Herceptin. These symbols will be available throughout the site during your session. Roche had a difficult 2020 with 5% revenue decline in local currencies due to CHF appreciating against USD (1% increase at constant exchange rates). A.) Selected leading drugs of pharmaceutical company Roche in 2020 and 2021, based on revenue (in million Swiss francs) [Graph]. Immunology Drugs : Immunology area deals with diseases in which the immune system attacks the body's own cells. The globalOncology. Roche's In Vitro Diagnostics segment has four subsegments: Centralised And Point of Care Solutions, Diabetes Care, Molecular Diagnostics and Tissue Diagnostics. Use Ask Statista Research Service. Table 59. Signaling growing interest in personalized oncology treatments as well as diagnostics, Roche plans a $2.4 billion acquisition that will expand its majority stake in Foundation Medicine into full ownership of the cancer-focused molecular diagnostics developer. and over 1Mio. Alecensa has seen strong growth from $184 million in 2016 to $650 million in 2018, and the sales could grow to $1.35 billion in 2021, given its presence in the lung cancer market. Show publisher information Roche currently has only one drug, Lucentis, in ophthalmology which it developed in collaboration with Novartis. Roche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products. By using the Site, you agree to be bound by our Terms of Roche's In Vitro Diagnostics segment has four subsegments: Centralised And Point of Care Solutions, Diabetes Care, Molecular Diagnostics and Tissue Diagnostics. Chart. Pfizer's top products based on revenue 2021, Pharmaceutical market: worldwide revenue 2001-2021, Novartis' top drugs based on revenue 2021, Top pharmaceutical products by sales worldwide 2021. Consensus EPS estimates are from QuoteMedia and are updated every weekday. drug manufactured by Roche Holding AG, sits in this arranged photograph in London, U.K. (Photographer: Chris Ratcliffe/Bloomberg), Diversifying With Gold, Bitcoin And Other Decentralized Assets, MSG Entertainment To Spin-Off Its Live Entertainment & MSG Network Businesses, Stock And Bond Investors: Prepare For A Favorable U.S. Inflation Report. F5 Inc. Stock Set For Bounce After Dismal Post-Earnings Performance? Roche will remain oncology market leader to 2023, in an increasingly fragmented but growing therapy area, says GBI Research. Whereas most finance sites simply give you the facts about where a stock has been and what a company has done in the past, Trefis focuses entirely on the future. CellCept is a medication to fight the body's own immune system, which can reject a kidney, liver, or heart transplant. ", Roche, Selected leading drugs of pharmaceutical company Roche in 2020 and 2021, based on revenue (in million Swiss francs) Statista, https://www.statista.com/statistics/266529/pharmaceutical-company-roche-top-drugs-based-on-revenue/ (last visited November 08, 2022), Selected leading drugs of pharmaceutical company Roche in 2020 and 2021, based on revenue, Available to download in PNG, PDF, XLS format, Drugs generating 10 billion U.S. dollars or more in annual sales worldwide 2021, Top global biopharma drugs by lifetime sales up to 2026, Top 50 pharmaceutical companies - Rx sales and R&D spending 2021, Sales of Johnson & Johnson's pharmaceutical products 2018-2021, Pharmaceutical company Roche: top drugs based on revenue 2020-2021, Price increase of top selling drugs U.S. 2016-2021, U.S. prices of Revlimid compared to prices in select countries 2020, Number of patent applications filed for top U.S. drugs 2022, Number of patents granted for the top selling U.S. drugs 2022, Leading therapy areas for U.S. drug spending 2020, U.S. top prescribed drugs based on sales 2021, Top pharma products by prescriptions U.S. 2020, Total savings of top generic drugs in U.S. 2021, Leading global pharmaceutical products by projected sales 2026, Leading U.S. pharmaceutical products by revenue 2026, Expiring patents for blockbuster and other small-molecule drugs worldwide 2020-2026, Top therapeutic categories worldwide 2022, by number of R&D products, Projected most valuable R&D projects based on net present value 2021, Top specialty drug pharmacies in the U.S. by revenue 2019, Number of approved ANDAs in U.S. 2009-2022, Gilead Sciences' top products based on revenue 2018-2021, Top specialty drug pharmacies in the U.S. based on market share 2019, Top metropolitan areas by largest employment indrugs and pharmaceuticals 2018, Top global drugs based on revenue in Q2 2012, Patent applications for genetic drugs worldwide 2010, Market size of branded biopharmaceuticals in China 2013-2023, Market size of biopharmaceuticals in China 2013-20225, Sales growth changes of patented drugs in Canada 2020, Pharmaceutical industry: global breakdown in the sale of new drugs 2004-2021, Drugs in R&D pipeline worldwide 2021 vs. 2022, by phase of development, Definition of specialty drugs by PBMs and pharmacy executives 2011, Narcolepsy drugs market size worldwide 2019-2030, Selected leading drugs of pharmaceutical company Roche in 2020 and 2021, based on revenue (in million Swiss francs), Find your information in our database containing over 20,000 reports, Find a brief overview of all Outlooks here, Tools and Tutorials explained in our Media Centre, research and development (R&D) expenditures. Oncology Drugs has decreased from $29 Bil in . Register in seconds and access exclusive features. Tecentriq is a relatively new drug for Roche, with potential sales of over $2.0 billion by 2021, given its series of approvals in recent years for bladder, lung, and breast cancer. Historically, cancer was treated as a single disease, but we now know that there are more than 200 different types, each with different behaviours, rates of growth and stages of progression. (Photo by Smith Collection/Gado/Getty Images). This division includes Roches Pegasys, Valcyte/Cymevene, Tamiflu among others. Some common viral diseases are influenza, HIV/AIDS and Hepatitis. However, we forecast the sales to decline to $1.3 billion in 2022, as the key drug in this portfolio Lucentis will lose its patent this year, resulting in generic competition. ~for more details. Clinical trials are carefully and rigorously designed, reviewed and evaluated to assess the efficacy and safety of new cancer therapies, that enables us to lead the delivery of new treatments to . Type a symbol or company name. New, Insights into the worlds most important health markets, Figures and insights about the advertising and media world, Everything you need to know about the industry development. Avastin was first approved by the U.S. FDA in 2004. PHESGO - the world's first fixed dose combination of two monoclonal antibodies in Oncology for the . Facebook: quarterly number of MAU (monthly active users) worldwide 2008-2022, Quarterly smartphone market share worldwide by vendor 2009-2022, Number of apps available in leading app stores Q2 2022, Research expert covering health, pharma & medtech, Profit from additional features with an Employee Account. Our team at PharmaShots has compiled a list of top 20 oncology companies based on their 2020 oncology revenue; In in the list of top 20 companies- BMS secured the top position with total revenue of $28B from oncology segment in 2020- followed by Roche and Merck with $26B & $15B; Oncology Segment Revenue: $0.23B. Ocrevus is used for the treatment of multiple sclerosis, which is a chronic disease that affects the central nervous system, especially the brain, spinal cord, and optic nerves. We estimate Ocrevuss share to increase from 0% in 2016 to. The company discovers, develops, and sells pharmaceutical products globally. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Most numbers within this article will be. facts. Key Professional Diagnostics product are CoaguChek and Accu-Chek. The figures are based on prescription medicine sales and include revenue from generics drugs. Roche Pharma India's patient assistance program - The Blue Tree addresses different barriers in the healthcare system and provides patients with sustainable solutions right from diagnosis until the completion of their treatment. Professional diagnostic helps in identifying indications in various therapeutic areas such as oncology, cardiovascular, virology, and infectious diseases. NAVIFY Oncology Hub provides a central workspace for clinicians to quickly access relevant patient data to optimise care decisions and enhance care coordination; NAVIFY Oncology Hub securely aggregates and organises patient data from disparate sources, providing a longitudinal view of the patient's cancer care journey; New digital solution streamlines clinical workflows and reduces . This is a BETA experience. See How its Powering New Collaboration and What-Ifs, For CFOs and Finance Teams | Product, R&D, and Marketing Teams. Oncology Drugs Market Report Outlines Revenue Share, SWOT Analysis and Supply Chain Outlook, Players Roche,Celgene,Johnson & Johnson,Pfizer,Sanofi,Bristol-Meyers Squibb December 22nd, 2021 . However, it will lose market exclusivity in 2019, and face generic competition from Pfizers Zirabev, a biosimilar for Avastin, and it is already approved in the EU. Roche merged with GenMark Diagnostics in March 2021 for $1.8 bln. These diseases are highly infectious in nature and are usually not detected at an early stage, which makes them difficult to target. : Diagnostic tests are medical tests performed to help in detection of diseases, conditions, or infections. Progress in cancer treatment has been made through molecular analysis and biomarker . Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services . Committed to innovation, quality, and service, we offer an extensive product portfolio featuring cutting-edge instruments and reagents for genome sequencing, microarray analysis, nucleic acid purification, real-time PCR, and cell analysis. On the upside, Perjeta has been doing well with sales growing from $1.9 billion in 2016 to $2.8 billion in 2018. we calculate$3 billion in expected lost sales. Please create an employee account to be able to mark statistics as favorites. The Roche and Foundation Medicine collaboration combines Roche's expertise and commitment in oncology with Foundation Medicine's leading technology, validation and experience in cancer profiling. However, some of the companys big ticket older drugs, including Rituxan, Avastin, and Herceptin are expected to see decline, as they face biosimilar competition. Roches oncology sales grew from $26.0 billion in 2015 to $29.1 billion in 2019. Exploreexample interactive dashboardsand create your own. In this analysis, we compare Roches oncology growth vis--vis its primary competitors and provide an outlook of the future course of business. However, Roche will likely be able to more than offset these declines over the next three years, primarily with its relatively newer drugs ~ Perjeta, Kadcyla, Tecentriq, and Alecensa.You can look at our interactive dashboard analysis ~How Can Roches New Drugs Add $5 Billion In Oncology Sales By 2021? See How its Powering New Collaboration and What-Ifs, ForCFOs and Finance Teams|Product, R&D, and Marketing Teams. (Photo by Smith Collection/Gado/Getty Images), Diversifying With Gold, Bitcoin And Other Decentralized Assets, MSG Entertainment To Spin-Off Its Live Entertainment & MSG Network Businesses, Stock And Bond Investors: Prepare For A Favorable U.S. Inflation Report. 4. Roche Holding (NASDAQ:RHHBY) can add $5 billion in new oncology drugs revenue between 2018-2021. Celgene Oncology Treatment Drug Product Offered None of the products due to enter the oncology market by 2023 are expected to reach the same levels of success as the highest revenue-generating drugs currently in the marketsuch as Revlimid, Opdivo, and Avastinaccording to business intelligence provider GBI Research. Roche will soon face biosimilar competition for its older oncology drugs ~ Avastin,. September 2021. Perjeta And Kadcyla Are Used For The Treatment of HER2 Positive Breast Cancer. As a Premium user you get access to background information and details about the release of this statistic. We expect the above trend to continue with slower growth in oncology sales, leading to a 45% share of oncology in Roches top line by 2021. Roche's Revenues have seen a increase of 12.4% from around $64 Bil in FY2019 to $72 Bil in FY2021 Revenue growth of about $8.0 Bil over 2019-2021 A.) Use. oche Has One of The Largest Oncology Drugs Portfolio, But It Is Expected To See A Decline Going Forward. This statistic was assembled from the Roche's annual report and the company's separated financial report. Like our charts? Roches diabetes care is focused on developing diagnostic instruments for detection of diabetes and also helps in glucose monitoring. Roche is a pioneer in oncology research with a very high success rate in early diagnosis and targeted therapy. The majority of this revenue was . These diseases include rheumatoid arthritis, Crohns disease, addison's disease, multiple sclerosis, and type I diabetes. ID: 5447648. Look at our interactive dashboard analysis on Roches Revenues for more details, parts of which are highlighted below. BCC Research. You can view our interactive dashboard analysis ~ Can Roches #1 Therapeutic Area With $28 Billion In Revenue Grow Further? Alecensa Is Used For The Treatment of Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer. A blister pack of Erlotinib 100mg tablets, also known by its brand name Tarceva, a cancer treatment [+] drug manufactured by Roche Holding AG, sits in this arranged photograph in London, U.K. (Photographer: Chris Ratcliffe/Bloomberg). In-Vitro Diagnostics revenue has grown from $11.4 billion in 2015 to $13.2 billion in 2019, and it could grow to $14.4 billion by 2022, partly led by immuno-diagnostics, which has seen strong growth in the recent past, and this trend could continue in the near term. The Roche Group reported CHF 15.97 billion ($17.31 billion) in total sales during the three months ended Sept. 30, up 8 percent from CHF 14.70 billion in Q3 2020. Industry-specific and extensively researched technical data (partially from exclusive partnerships). Revenues for the pharmaceutical division came in at CHF 11.71 billion, up 5 percent compared to CHF 11.12 billion during Q3 2020. Up 15% In A Month Will Honeywell Stock Continue Its Uptrend? Roche Holding AG annual revenue for 2019 was $64.165B, a 5.48% increase from 2018. Learn more about how Statista can support your business. Please do not hesitate to contact me. Roche's Oncology Drugs segment to make 43% of $64.0 billion in Roche's 2020 revenues, but Roche's Neuroscience Drugs segment is key to the company's revenue growth, (2) In Vitro Diagnostics : $13.7 billion (21%), (3) Immunology Drugs : $8.8 billion (14%), (4) Other Therapeutic Drugs : $5.8 billion (9%), (5) Neuroscience Drugs : $5.2 billion (8%), (6) Opthalmology Drugs : $1.6 billion (2%), (7) Infectious Diseases Drugs : $1.0 billion (2%), ------------------------------------------------------------------------------, + Change in Oncology Drugs : $1.1 billion, + Change in In Vitro Diagnostics : $1.7 billion, + Change in Immunology Drugs : $0.9 billion, + Change in Other Therapeutic Drugs : $2.1 billion, + Change in Neuroscience Drugs : $3.6 billion, + Change in Opthalmology Drugs : $0.1 billion, + Change in Infectious Diseases Drugs : $-0.4 billion, Below we discuss Roche's business model, followed by sections that review past performance as well as expectations for Roche's revenue drivers for 2020 and 2021, along with competitive comparisons with peers Pfizer and Merck & Co, Inc. Roche primarily serves the pharmaceuticals and diagnostics products markets.
Desmos Logarithmic Regression,
Delete Expired Objects S3,
Apple Configurator Macbook,
Does Moving Apps To Sd Improve Performance,
Arturia Minilab Mk2 Midi Control Center,
Slicked Up - Crossword Clue,
Continental Valve Extension,